Vaxcyte, Inc.
A clinical-stage biotech making vaccines with its XpressCF cell-free protein synthesis platform, which builds conjugate shots without the immune-dampening carrier proteins that limit conventional pneumococcal vaccines. Its lead candidates, VAX-31 and VAX-24, aim at pneumococcal disease in adults and children, and its pipeline also covers strep and shigellosis. The company gained control of its cell-free extract manufacturing through an agreement with Sutro Biopharma.
Granted 29.5K · Sold 74.0K
Granted 846.2K · Sold 579.9K
Granted 459.3K · Sold 264.1K
Granted 396.0K · Sold 142.1K
Granted 74.9K · Sold 9.7K
Granted 126.7K · Sold 80.5K
Granted 78.5K · Sold 45.7K
Granted 53.5K · Sold 34.0K
Granted 7.2K
Granted 10.0K · Sold 38.3K
Granted 30.7K · Sold 18.2K
Granted 25.0K · Sold 12.5K
Granted 12.5K
Granted 18.1K
Granted 6.9K
Granted 5.6K
Granted 5.3K
Granted 4.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairman JeffVP, Research · 25 transactions | — | 674.1Kas of Jan 2023 | 29.5K | — | 74.0K |
| Pickering GrantCHIEF EXECUTIVE OFFICER, Director · 218 transactions | — | 586.7K | 846.2K | — | 579.9K |
| Guggenhime AndrewPRESIDENT AND CFO · 123 transactions | — | 238.1K | 459.3K | — | 264.1K |
| Wassil JimCHIEF OPERATING OFFICER · 132 transactions | +771.7% | 158.5K | 396.0K | — | 142.1K |
| Dhaliwal Harpreet S.Chief Technical Ops Officer · 12 transactions | — | 76.0K | 74.9K | — | 9.7K |
| Eydelman MikhailSVP, GEN COUNSEL & CORP SEC · 91 transactions | — | 41.7Kas of Mar 2025 | 126.7K | — | 80.5K |
| Cowan ElviaSVP, Finance & CAO · 37 transactions | — | 32.0K | 78.5K | — | 45.7K |
| Lukatch HeathDirector · 29 transactions | — | 19.5K | 53.5K | — | 34.0K |
| Hirth PeterDirector · 3 transactions | — | 14.3Kas of Jun 2024 | 7.2K | — | — |
| Sauer PaulSVP Process Dev, Manufacturing · 12 transactions | -65.1% | 13.8Kas of Sep 2022 | 10.0K | — | 38.3K |
| Gilbert Halley EDirector · 7 transactions | — | 12.5K | 30.7K | — | 18.2K |
| Loxam TeriDirector · 19 transactions | — | 12.5K | 25.0K | — | 12.5K |
| Drapeau Anne SDirector · 5 transactions | — | 12.5K | 12.5K | — | — |
| Paya Carlos VDirector · 9 transactions | — | 12.5K | 18.1K | — | — |
| Lee JacksDirector · 3 transactions | — | 6.9K | 6.9K | — | — |
| Kamarck Michael E.Director · 2 transactions | — | 5.6Kas of Jun 2023 | 5.6K | — | — |
| Furey JohnDirector · 2 transactions | — | 5.3K | 5.3K | — | — |
| Brandicourt OlivierDirector · 3 transactions | — | 4.7K | 4.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.30M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.